Skip to main
STOK

STOK Stock Forecast & Price Target

STOK Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 13%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Stoke Therapeutics Inc exhibits a promising outlook due to the increasing revenue projections for its lead asset, zorevunersen, with expectations of launch in FY28 and potential revenue targets raised to $32, reflecting growing confidence in its market entry. The company's Phase I/II study data indicates robust seizure reduction of approximately 82% and meaningful cognitive benefits, which not only strengthens the case for zorevunersen as a viable treatment for Dravet syndrome but also de-risks the upcoming Phase 3 EMPEROR study. Furthermore, the possibility of expedited FDA approval could elevate revenue expectations even further, potentially pushing targets into the low-$40s, underscoring the strong market potential for Stoke Therapeutics's pipeline.

Bears say

Stoke Therapeutics has experienced a significant decline in share price, dropping 15% in reaction to market events affecting a related company, indicating heightened volatility and investor concern. The company's future valuation is at risk, contingent upon the issuance and protection of key patents, as any disputes or failures in securing these patents could negatively impact market success and financial projections. Additionally, the company faces stiff competition in the Dravet market, where existing therapies have captured over 20% market share, raising questions about the potential adoption and long-term benefits of its lead product, zorevunersen.

STOK has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 13% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stoke Therapeutics Inc (STOK) Forecast

Analysts have given STOK a Strong Buy based on their latest research and market trends.

According to 8 analysts, STOK has a Strong Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stoke Therapeutics Inc (STOK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.